IP Library › Granted Patent US 10,092,452
Granted Patent B2
US 10,092,452 · App. 14/579,450 · Granted Oct 9, 2018

Targeted delivery of magnetically tagged active agents in combination with negative pressure wound therapy

Inventors: Timothy Mark Robinson (Basingstoke, GB); Christopher Brian Locke (Bournemouth, GB)
Assignee: KCI Licensing, Inc.
A61F13/00063A61F13/00068A61M1/0088A61N1/40A61M2202/0437A61N2/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,092,452
App. No.
14/579,450
Granted
Oct 9, 2018
Kind
B2
Abstract

Methods and systems for treating a wound using targeted delivery of magnetically-tagged active agents in combination with negative pressure wound therapy are presented. In particular, a magnetically-active wound insert may be used to attract magnetically-tagged stem cells to a wound site to treat the wound.

Claims (25)

1. A wound treatment system for use in treating tissue at a wound site in patient, comprising:

a wound dressing comprising:

a drape adapted to be coupled to skin adjacent to the wound such that the drape covers the wound and forms a space between the drape and the wound; and

a wound insert disposed within the space configured to attract a magnetically-tagged therapeutic agent to the tissue and increase exposure of the tissue to the agent, the wound insert comprising a magnetic material; and

a delivery member configured to provide the magnetically-tagged therapeutic agent.

2. The system of claim 1 , where the magnetic material comprises magnetic particles dispersed in the wound insert.

3. The system of claim 2 , where the magnetic particles comprise superparamagnetic iron oxide.

4. The system of claim 1 , where the wound insert comprises open-celled foam.

5. The system of claim 4 , where the wound insert comprises open-celled reticulated foam.

6. The system of claim 1 , where the magnetic material comprises a permanent magnet.

7. The system of claim 1 , wherein the delivery member is adapted to deliver the magnetically-tagged therapeutic agent to a tissue site adjacent to the wound.

8. The system of claim 1 , wherein the delivery member comprises a patch adapted to be applied to a tissue site adjacent to the wound.

9. The system of claim 1 , wherein the delivery member is adapted for systemically injecting the magnetically-tagged therapeutic agent into the patient.

10. The system of claim 1 , further comprising a negative pressure source configured to be coupled to the wound dressing.

11. A wound treatment system for treatment of a wound, comprising:

a wound insert adapted to be disposed adjacent to the wound and configured to attract a magnetically-tagged therapeutic agent to the wound so as to increase exposure of the wound to the agent, the wound insert comprising an open-celled foam member and magnetic particles coated on or dispersed in the foam member;

a negative pressure source;

a conduit in fluid communication with the negative pressure source, configured to deliver an instillation fluid to the wound, to remove fluid from the wound, and to apply negative pressure to the wound; and

a delivery member configured to provide the magnetically-tagged therapeutic agent to a site not in the wound.

12. The system of claim 11 , wherein the magnetic particles are coated on an exterior surface of the foam member.

13. The system of claim 11 , wherein the magnetic particles are disposed within the interior portion of the foam member.

14. The system of claim 11 , further comprising a drape coupled to the skin adjacent the wound of a patient such that the drape covers the wound and the wound insert.

15. The system of claim 11 , wherein the delivery member comprises a patch adapted to be applied to a tissue site adjacent to the wound.

16. The system of claim 11 , wherein the delivery member is adapted for systemically injecting the magnetically-tagged therapeutic agent into the patient.

17. The system of claim 11 , wherein the magnetic particles are superparamagnetic iron oxide nanoparticles.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2015
From: ROBINSON, TIMOTHY MARK; LOCKE, CHRISTOPHER BRIAN
To: KCI LICENSING, INC.
Reel/Frame 035118/0905 →
Continuity (3)
Continuation 13323049 · Dec 12, 2011
Provisional Application 61423459 · Dec 15, 2010
Related Publication 20150112288A1 · Apr 23, 2015
Cited By (1)
US 12,521,484